FDA Brief

Warning letters Biologics

FDA warning letter to

InVia Fertility Specialists, PLLC

High riskIssued Jun 13, 2025Posted Jul 1, 2025Center for Biologics Evaluation and Research

FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.

What happened

FDA inspected InVia Fertility Specialists in Hoffman Estates, IL, from January 28 to February 5, 2025, and found violations of the human cell and tissue donor eligibility rules. The letter says an anonymous oocyte donor was not tested for HIV-1, HCV, and HBV by the required method, donor records lacked medical history interviews and physical exams, eligibility was not determined or documented for about six anonymous and four directed oocyte donors, and some tissue products from reactive donors lacked required biohazard labels. FDA said the firm’s February 25, 2025 response lacked enough detail and noted two violations from a September 2022 inspection recurred.

What FDA found

  1. Failed to test a specimen from an anonymous oocyte donor for HIV-1, HCV, and HBV by the required method before tissue products were transferred to a recipient.

    21 CFR 1271.85(a)
  2. Failed to screen donors by reviewing relevant medical records; records for anonymous oocyte and directed semen donors lacked medical history interviews and, for semen donors, physical exam reports.

    21 CFR 1271.75(a)(1)
  3. From January 2023 through November 2024, failed to determine and document donor eligibility for about six anonymous oocyte donors and four directed oocyte donors.

    21 CFR 1271.50(a)
  4. Failed to prominently label tissue products from ineligible directed reproductive donors with the biohazard warning symbol and required warning statements when donors tested reactive.

    21 CFR 1271.65(b)(2)
  5. Failed to establish and maintain procedures covering physical examination, complete communicable disease testing, and responsible-person donor eligibility determination and documentation.

    21 CFR 1271.47(a)

What FDA wants

FDA asks InVia to respond in writing within 15 working days with specific corrective steps, supporting documentation, and a plan to prevent recurrence. FDA also says to keep tissue products from donors with incomplete screening or testing in quarantine unless FDA grants an exemption or alternative.

Who should pay attention

  • fertility clinics and oocyte/semen donor programs
  • IVF laboratories and tissue banks
  • recipients of donor eggs, sperm, or embryos

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk